EPISODE · Jun 12, 2020 · 23 MIN
Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers
from CEimpact Podcast · host Pharmacy Podcast Network
Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID, is the subject of this episode.This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.Follow CEimpact on Social Media:LinkedInInstagram
What this episode covers
Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID, is the subject of this episode.This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.Follow CEimpact on Social Media: LinkedIn Instagram
NOW PLAYING
Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m